Brokerages Set Cempra Inc. (CEMP) Target Price at $18.35
Shares of Cempra Inc. (NASDAQ:CEMP) have received an average recommendation of “Hold” from the sixteen analysts that are covering the company. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $17.67.
A number of research firms recently issued reports on CEMP. Jefferies Group set a $40.00 target price on shares of Cempra and gave the company a “buy” rating in a research report on Monday, October 24th. Needham & Company LLC reiterated a “buy” rating and set a $48.00 target price on shares of Cempra in a research report on Wednesday, October 26th. Zacks Investment Research downgraded shares of Cempra from a “buy” rating to a “hold” rating in a research report on Thursday, August 11th. Roth Capital set a $34.00 target price on shares of Cempra and gave the company a “buy” rating in a research report on Friday, October 28th. Finally, Raymond James Financial Inc. initiated coverage on shares of Cempra in a research report on Tuesday, September 13th. They set an “outperform” rating and a $32.00 target price on the stock.
Cempra (NASDAQ:CEMP) opened at 6.50 on Thursday. The stock has a 50 day moving average of $18.75 and a 200-day moving average of $19.34. Cempra has a 12 month low of $5.70 and a 12 month high of $34.24. The company’s market cap is $340.48 million.
Cempra (NASDAQ:CEMP) last released its earnings results on Thursday, October 27th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.02. Cempra had a negative net margin of 678.72% and a negative return on equity of 59.94%. The company had revenue of $4 million for the quarter, compared to the consensus estimate of $3.90 million. During the same quarter in the previous year, the company earned ($0.63) EPS. Cempra’s quarterly revenue was up 60.0% compared to the same quarter last year. Equities research analysts expect that Cempra will post ($2.42) EPS for the current year.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Cempra by 0.4% in the third quarter. BlackRock Inc. now owns 4,590 shares of the company’s stock valued at $111,000 after buying an additional 17 shares during the last quarter. Advisor Group Inc. raised its position in Cempra by 2,258.0% in the third quarter. Advisor Group Inc. now owns 6,508 shares of the company’s stock valued at $157,000 after buying an additional 6,232 shares during the last quarter. Legal & General Group Plc raised its position in Cempra by 5.8% in the second quarter. Legal & General Group Plc now owns 7,102 shares of the company’s stock valued at $117,000 after buying an additional 391 shares during the last quarter. Prudential Financial Inc. bought a new position in Cempra during the third quarter valued at $202,000. Finally, SG Americas Securities LLC bought a new position in Cempra during the third quarter valued at $363,000. Institutional investors own 78.45% of the company’s stock.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.
Receive News & Stock Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related stocks with our FREE daily email newsletter.